CME/CE
ReachMD
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Location:
United States
Networks:
ReachMD
Description:
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Language:
English
Website:
http://reachmd.com/programs/cme/
Episodes
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
5/15/2024
Host: Jhanelle E. Gray, MD
Guest: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:05:59
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
5/15/2024
Host: Joshua E. Reuss, MD
Guest: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:05:29
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
5/15/2024
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:04:29
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
5/15/2024
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:06:00
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
5/15/2024
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:05:29
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
5/15/2024
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:04:30
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
5/15/2024
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:04:00
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
5/15/2024
Host: Jhanelle E. Gray, MD
Guest: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:05:29
Accurate Staging and Determining Resectability in NSCLC
5/15/2024
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Duration:00:04:59
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
5/14/2024
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Duration:00:05:28
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
5/14/2024
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Duration:00:05:29
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
5/14/2024
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Duration:00:05:29
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
5/9/2024
Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.
Duration:00:28:56
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
5/9/2024
Host: Marianna Fontana, MD
Guest: Ronald Witteles, MD
Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss this opportunity to gain valuable insights and elevate your understanding of ATTR-CM treatment strategies!
Duration:00:12:25
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
5/6/2024
Host: Arshad M. Khanani, MD, MA
Guest: Karl Csaky, MD, PhD
Guest: Christina Y. Weng, MD, MBA, FASRS
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.
Duration:00:56:55
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
5/3/2024
Host: Craig M. McDonald, MD
Guest: Crystal Proud, MD
Guest: Aravindhan Veerapandiyan, MD
There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies.
Duration:00:44:58
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
5/3/2024
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Duration:00:05:59
Managing Immune-Related Adverse Events With Immunotherapies
5/3/2024
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Duration:00:05:59
Overcoming Barriers to Equitable Care in HNSCC
5/3/2024
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Duration:00:05:29
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
5/3/2024
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Duration:00:05:59